Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes
- PMID: 29222350
- DOI: 10.1136/annrheumdis-2017-212078
Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes
Abstract
Objectives: Leflunomide is known to be embryotoxic and teratogenic in rodents. However, there is less evidence in humans. We quantified the risk of major congenital malformation (MCM), prematurity, low birth weight (LBW) and spontaneous abortion associated with leflunomide exposure during pregnancy in humans.
Methods: From a cohort of 289 688 pregnancies in Montreal, Quebec, Canada, from 1998 to 2015, first-trimester leflunomide exposure and other antirheumatic drug exposures were studied for their association with MCM and spontaneous abortions. Also second or third-trimester leflunomide exposures were examined for associations with prematurity and LBW. Logistic regression model-based generalised estimating equations were used.
Results: 51 pregnancies were exposed to leflunomide during the first trimester, and 21 during the second/third trimesters. Adjusting for potential confounders, use of leflunomide during the first trimester of pregnancy was not associated with the risk of MCM (adjusted OR (aOR) 0.97, 95% CI 0.81 to 1.16; 5 exposed cases). No association was found between second/third-trimester exposure to leflunomide and the risk of prematurity (aOR 4.03, 95% CI 0.91 to 17.85; 7 exposed cases) nor LBW (aOR 1.06, 95%CI 0.90 to 1.25; 8 exposed cases). Pregnancy exposure to leflunomide was also not associated with the risk of spontaneous abortion (aOR 1.09, 95% CI 0.90 to 1.32; 11 exposed cases).
Conclusions: Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions. However, given that relatively few women were exposed to leflunomide during pregnancy in this cohort, caution remains warranted.
Keywords: Leflunomide; low birth weight; major congenital malformation; pregnancy exposure; spontaneous abortion.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: AB and JPZ declare no financial interest relating to the subject discussed in the manuscript; IS and SC are employees of Sanofi.
Similar articles
-
Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.Sci Rep. 2021 Sep 29;11(1):19302. doi: 10.1038/s41598-021-97092-y. Sci Rep. 2021. PMID: 34588467 Free PMC article.
-
Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes.J Allergy Clin Immunol. 2016 Jul;138(1):97-104.e7. doi: 10.1016/j.jaci.2016.01.021. Epub 2016 Apr 1. J Allergy Clin Immunol. 2016. PMID: 27045580
-
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.J Clin Psychiatry. 2006 Aug;67(8):1280-4. doi: 10.4088/jcp.v67n0817. J Clin Psychiatry. 2006. PMID: 16965209
-
Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis.Br J Dermatol. 2015 Nov;173(5):1132-41. doi: 10.1111/bjd.14053. Epub 2015 Oct 19. Br J Dermatol. 2015. PMID: 26215715 Review.
-
Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.Drug Saf. 2007;30(3):247-64. doi: 10.2165/00002018-200730030-00006. Drug Saf. 2007. PMID: 17343431 Review.
Cited by
-
2022 Chinese guideline for the management of pregnancy and reproduction in systemic lupus erythematosus.Rheumatol Immunol Res. 2023 Sep 27;4(3):115-138. doi: 10.2478/rir-2023-0019. eCollection 2023 Sep. Rheumatol Immunol Res. 2023. PMID: 37781682 Free PMC article. Review.
-
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551. Rheumatology (Oxford). 2023. PMID: 36318966 Free PMC article. No abstract available.
-
Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report.Clin Drug Investig. 2022 Sep;42(9):787-789. doi: 10.1007/s40261-022-01185-z. Epub 2022 Jul 27. Clin Drug Investig. 2022. PMID: 35896855 No abstract available.
-
[Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding].Z Rheumatol. 2021 Oct;80(8):716-725. doi: 10.1007/s00393-021-01095-z. Epub 2021 Sep 28. Z Rheumatol. 2021. PMID: 34581874 Free PMC article. Review. German.
-
Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update.Arch Gynecol Obstet. 2021 Nov;304(5):1153-1160. doi: 10.1007/s00404-021-06178-5. Epub 2021 Aug 14. Arch Gynecol Obstet. 2021. PMID: 34390384 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical